Presentations at scientific conferences

Lachaine J, Bibeau J, Castonguay A, Piché-Richard V, Barakat S
Systematic review on the correlation between lung function or eosinophil levels and quality of life in asthma
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 7-11, 2015, Milano

Lachaine J, Bibeau J, Castonguay A, Piché-Richard V, Barakat S
Systematic review on the correlation between lung function or eosinophil levels and health care resource utilization in asthma
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 7-11, 2015, Milano

Lachaine J, Bibeau J, Castonguay A, Barakat S
Cost and resource utilization of uncontrolled and persistent asthma in Canada: a systematic literature review
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 7-11, 2015, Milano

Lachaine J, Lambert-Obry V, Lemay M
Literature review of economic evaluations of screening tests for breast cancer
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 7-11, 2015, Milano

Beauchemin C, Lapierre ME, Letarte N, Yelle L, Lachaine J
How to conduct economic evaluations of new treatments for advanced cancer when overall survival data are not available? Results from a systematic literature review
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 7-11, 2015, Milano

Lachaine J, Gaudet D, Miron A, Tremblay K
Hospitalizations in hyperchylomicronemia patients in Quebec, Canada; results from a real-world observational study
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 7-11, 2015, Milano

Lachaine J, Benmouhoub I, Mathurin K
Economic evaluations of glioblastoma
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 7-11, 2015, Milano

Lachaine J, Bibeau J, Mathurin K, Miron A, Beauchemin C, Benmouhoub I, Bouchama N, Cadieux-Chalifour S, Castonguay A, Charron JN, Enckle G, Hasani I, Lambert-Obry V, Lapierre ME, Piché-Richard V
Systematic review of economic evaluations in personalized medicine
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 7-11, 2015, Milano

Lachaine J, Laberge AM, Bibeau J, Lambert-Obry V
Systematic review of economic evaluations of treatments in epilepsy
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 7-11, 2015, Milano

Blais R, Lachaine J, Abrahamowicz M, Latimer É, Tamblyn R
Does free medications improve observance among diabetic patients?
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 7-11, 2015, Milano

Lachaine J, Benmouhoub I, Mathurin K
The economic burden of primary brain tumors in Canada
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 7-11, 2015, Milano

Lachaine J, Miron A, Nait Ladjemil D
Economic evaluations of treatments for inflammatory bowel diseases
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 7-11, 2015, Milano

Lachaine J, Cyr MC, Mtibaa M, Raymond V, Duong A
Patient’s adherence to oral anticoagulants in atrial fibrillation
Canadian Association for Population Therapeutics (CAPT), Nov 2-3, 2015, Toronto

Lachaine J, Cyr MC, Mtibaa M, Raymond V, Duong A
Early experience with apixaban in stroke prevention in patients with atrial fibrillation: an analysis of the RAMQ database
Canadian Cardiovascular Congress, Oct 24-27, 2015, Toronto

Cyr MC, Bissonnette R, Lachaine J
Effects of methotrexate on the risk of myocardial infarction among Canadian patients with psoriasis and psoriatic arthritis
International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Aug 22-26, 2015, Boston

Lachaine J, Lachance S, Lambert-Obry V, Bibeau J
Systematic review of economic evaluations in allogeneic hematopoietic stem cell transplantation
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 16-20, 2015, Philadelphia

Lachaine J, Lambert-Obry V, Gaumond S, Desjardins O
Impact of biologics use on depression and anxiety frequency and health care resource utilization in psoriasis: an analysis using the Quebec provincial drug reimbursement program database
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 8-12, 2014, Amsterdam

Gouault-Laliberté A, Bergeron C, Lachaine J
Resources utilization for the investigation of pulmonary nodules in a university hospital center in Quebec, Canada
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 8-12, 2014, Amsterdam

Mathurin K, Beauchemin C, Lachaine J
Validation of a global economic model to evaluate the cost-effectiveness of targeted treatments using companion diagnostics in advanced/metastatic cancer treatment using KRAS testing for cetuximab therapy in metastatic colorectal cancer
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 8-12, 2014, Amsterdam

Mathurin K, Beauchemin C, Lachaine J
Development of a global economic model to evaluate the cost-effectiveness of targeted treatments using companion diagnostics in advanced/metastatic cancer treatment
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 8-12, 2014, Amsterdam

Zhang E, Wartelle-Bladou C, Lepanto L, Lachaine J, Cloutier G, Tang A
Cost-utility analysis of screening strategies for nonalcoholic steatohepatitis
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 8-12, 2014, Amsterdam

Lachaine J, Lapierre ME, Abdalla N, Rouleau A, Stip E
Treatment patterns of long-acting injectable antipsychotics in the province of Quebec
International College of Neuropsychopharmacology (CINP), Jun 24-26, 2014, Vancouver

Lachaine J, Lapierre ME, Abdalla N, Rouleau A, Stip E
Healthcare costs before and after initiation of long-acting injectable antipsychotics in the province of Quebec
International College of Neuropsychopharmacology (CINP), Jun 24-26, 2014, Vancouver

Lachaine J, Lapierre ME, Beauchemin C, Angyalosi G, Balp MM, Calado F, Debonnett L, Desforges J, Sagkriotis A
Real world evidence on inhaled tobramycin use in CF patients: analysis of the RAMQ data (Canada)
European Cystic Fibrosis Conference (ECFC), Jun 11-14, 2014, Gothenburg

Esfahani K, Agulnik JS, Batist G, Brandao G, Tremblay L, Blais N, Kempen LV, Lachaine J, Rousseau C, Cohen V
Biopsy-driven study to identify mechanisms of resistance to crizotinib and to evaluate real-world pharmacoeconomics in advanced ALK-positive NSCLC patients
American Society of Clinical Oncology (ASCO), May 30-Jun 3, 2014, Chicago

Lachaine J, Miron A, Beauchemin C
Economic evaluations of treatments for inflammatory bowel diseases
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 1-3, 2014, Montreal

Lachaine J, Mathurin M, Beauchemin C
Parameter values associated with the development of a global economic model to value companion diagnostics in advanced/metastatic cancer treatment
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 1-3, 2014, Montreal

Lachaine J, Savoie M, Bibeau J
Real-world clinical evidence development: an analysis of relevant international models for the potential implementation of such a program in Quebec
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 1-3, 2014, Montreal

Lachaine J, Lambert-Obry V
Cost-effectiveness of stiripentol in the treatment of severe myoclonic epilepsy in infancy in Canada
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 1-3, 2014, Montreal

Lachaine J, Lapierre ME, Lakhdari K
Chronic obstructive pulmonary disease (COPD) drug utilization: an analysis with the RAMQ database
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 1-3, 2014, Montreal

Lachaine J, Vachon ML, Lambert-Obry V, Beauchemin C
Costs of adverse events associated with treatment of hepatitis C virus infection: an analysis using the Quebec provincial drug reimbursement program database
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 1-3, 2014, Montreal

Lachaine J, Lapierre ME, Abdalla N, Rouleau A, Stip E
Resource use and associated costs of long acting injectable antipsychotics: a RAMQ database analysis
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 1-3, 2014, Montreal

Lachaine J, Lapierre ME, Abdalla N, Rouleau A, Stip E
Long-acting injectable antipsychotics treatment patterns: a RAMQ database analysis
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 1-3, 2014, Montreal

Lachaine J, Mathurin K, Barakat S
Cost-effectiveness of arsenic trioxide + all-trans retinoic acid compared with all-trans retinoic acid + idarubicin in the treatment of newly diagnosed acute promyelocytic lymphoma leukemia in Canada
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 1-3, 2014, Montreal

Lachaine J, Mathurin K, Barakat S
Cost-effectiveness of arsenic trioxide in the treatment of relapsed/refractory acute promyelocytic lymphoma leukemia in Canada
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 1-3, 2014, Montreal

Lachaine J, Sikirica V, Mathurin K
Cost-effectiveness of guanfacine extended-release versus atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder in Canada
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 1-3, 2014, Montreal

Lachaine J, Sikirica V, Mathurin K
Cost-effectiveness of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant versus long-acting stimulant monotherapy for the treatment of attention-deficit/hyperactivity disorder in Canada
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 1-3, 2014, Montreal

Lachaine J, Ben Amor L, van Stralen J, Sikirica V, Hodgkins P, De G, Yang H, Heroux J
Health care resource utilization and costs associated with atypical antipsychotics use in children and adolescents with attention deficit/hyperactivity disorder in Quebec, Canada
Canadian Agency for Drugs and Technologies in Health (CADTH), Jun 6-9, 2014, Gatineau

Lachaine J, Baril JP, Lambert-Obry V, Beauchemin C
Comparison of compliance rates and health care resource utilization between antiretroviral treatment (ART) regimens: an analysis using the Quebec provincial drug reimbursement program database
Canadian Conference on HIV/AIDS Research (CAHR), May 1-4, 2014, St-John

Lachaine J, Vachon ML, Lambert-Obry V, Beauchemin C
Hepatitis C virus infection treatment patterns and associated costs: an analysis of the Quebec provincial reimbursement program database
Canadian Digestive Diseases Week/Canadian Association for the Study of the Liver (CDDW/CASL), Feb 8-11, 2014, Toronto

Lachaine J, Mathurin K, Barakat S
Cost-effectiveness of arsenic trioxide + all-trans retinoic acid compared with all-trans retinoic acid + idarubicin in the treatment of newly diagnosed acute promyelocytic leukemia in Canada
American Society of Hematology (ASH), Dec 8-10, 2013, New Orleans

Lachaine J, Mathurin K, Barakat S
Cost-effectiveness of arsenic trioxide in the treatment of relapsed/refractory acute promyelocytic leukemia in Canada
American Society of Hematology (ASH), Dec 8-10, 2013, New Orleans

Sikirica V, van Stralen J, Cloutier M, Ben Amor L, Hodgkins P, Carter V, Guerin A, Lachaine J
Treatment patterns in ADHD children/adolescents using atypical antipsychotics in Quebec
Canadian Academy of Child and Adolescent Psychiatry (CACAP), Nov 17-19, 2013, Vancouver

Lachaine J, Vachon ML, Lambert-Obry V, Beauchemin C
Hepatitis C virus infection treatment completion: an analysis of the Quebec provincial reimbursement program database
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 2-6, 2013, Dublin

Lachaine J, Vachon ML, Lambert-Obry V, Beauchemin C
Cost associated with adverse events and health care resources utilization in hepatitis C virus infection in Quebec, Canada
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 2-6, 2013, Dublin

Lachaine J, Baril JP, Lambert-Obry V, Beauchemin C
Health care resource utilization and adherence to antiretroviral treatment (ART) by HIV patients: an analysis with the Quebec (Canada) public drug plan database
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 2-6, 2013, Dublin

Lachaine J, Sikirica V, De G, van Stralen J, Ben Amor L, Hodgkins P, Yang H, Heroux J
Health care resource utilization and costs associated with atypical antipsychotics use in children and adolescents with attention deficit/hyperactivity disorder in Quebec, Canada
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 2-6, 2013, Dublin

Lachaine J, Lapierre ME, Beauchemin C, Balp MM, Calado F, Debonnett L, Desforges J, Sagkriotis A
Tobramycin powder for inhalation for the treatment of cystic fibrosis: analysis of the RAMQ data
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 2-6, 2013, Dublin

Lachaine J, Lambert-Obry V, Dionne PA
Potential predictors of Alzheimer’s disease: an analysis with the Quebec provincial drug reimbursement program database
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 2-6, 2013, Dublin

Lachaine J, Lambert-Obry V, Dionne PA
Health care resources utilization in Alzheimer’s disease: an analysis with the Quebec provincial drug reimbursement program database
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 2-6, 2013, Dublin

Lachaine J, Vachon ML, Lambert-Obry V, Beauchemin C
Health care resources utilization in hepatitis C virus infection and cost associated with adverse events: an analysis of the Quebec provincial drug reimbursement program database
American Association for the Study of Liver Diseases (AASLD), Nov 1-5, 2013, Washington DC

Lachaine J, Beauchemin C
Trends in health care resources utilization, cost and medication selection in the treatment of diabetes
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Latin America Congress, Sep 12-14, 2013, Buenos Aires

Lachaine J, Baril JP, Beauchemin C, Lambert-Obry V
Compliance to antiretroviral agents (ART) and health care resource utilization by HIV patients: an analysis with the Quebec (Canada) public drug plan database
Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Sep 10-13, 2013, Denver

Lachaine J, Sikirica V, Cloutier M, Ben Amor L, Hodgkins P, van Stralen J, Carter V, Guerin A
Period prevalence of therapy combination and switching among children and adolescents with attention deficit/hyperactivity disorder (ADHD) treated with stimulants in the Canadian province of Quebec
International Conference on Pharmacoepidemiology (ISPE), Aug 25-28, 2013, Montreal

Levesque A, Bissonnette R, Prefontaine S, Lapierre ME, Lachaine J
Relative risk of myocardial infarction for Canadian patients with psoriasis treated systemically as compared to patients treated with phototherapy
International Conference on Pharmacoepidemiology (ISPE), Aug 25-28, 2013, Montreal

Levesque A, Bissonnette R, Prefontaine S, Lachaine J
Relative risk of myocardial infarction for Canadian patients with psoriasis treated systemically as compared to patients treated with phototherapy
Canadian Dermatologic Association (CDA), Jun 27-30, 2013, Quebec

Ben Amor L, Sikirica V, De G, Lachaine J, van Stralen J, Heroux J, Yang H, Hodgkins P
Therapy combination: a prevalent pattern among children and adolescents with attention deficit/hyperactivity disorder treated with stimulants in the canadian province of Quebec
4th World Congress on ADHD (WCADHD), Jun 6-9, 2013, Milan

Mathurin K, Beauchemin C, Lachaine J
Economic evaluations of companion diagnostics in cancer therapy
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 18-22, 2013, New Orleans

Mathurin K, Beauchemin C, Lachaine J
The cost-effectiveness of companion diagnostics in cancer therapy
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 18-22, 2013, New Orleans

Lachaine J, Beauchemin C, Mathurin K, Aissa F
Cost-effectiveness of bendamustine versus ibritumomab tiuxetan in the treatment of rituximab-refractory indolent Non-Hodgkin’s lymphoma in Canada
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 18-22, 2013, New Orleans

Lachaine J, Beauchemin K, Mathurin K, Aissa F
Cost-effectiveness of bendamustine + rituximab versus fludarabine + rituximab in the treatment of relapsed indolent Non-Hodgkin’s and mantle cell lymphomas in Canada
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 18-22, 2013, New Orleans

Lachaine J, Beauchemin C, Lapierre ME, Snow LA
Treatment patterns in pediatric antibiotic formulations: an analysis of the RAMQ database
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 18-22, 2013, New Orleans

Lachaine J, Beauchemin C, Lapierre ME, Snow LA
Utilization trends of various formulations of testosterone: an analysis of the RAMQ database
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 18-22, 2013, New Orleans

Lachaine J, Beauchemin C, Lambert-Obry V, Chiva-Razavi S
Economic burden associated with ulcerative colitis in Canada: an analysis using the RAMQ database
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 18-22, 2013, New Orleans

Lachaine J, Beauchemin C, Desjardins O
Use of biologic agents in the treatment of psoriasis: an analysis of the Quebec provincial drug reimbursement program database
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 18-22, 2013, New Orleans

Lachaine J, Beauchemin C, Desjardins O
Use of biologic agents in the treatment of rheumatoid arthritis: an analysis of the Quebec provincial drug reimbursement program database
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 18-22, 2013, New Orleans

Lachaine J, Beauchemin C, Chiva-Razavi S
Treatment patterns of adalimumab and infliximab in the treatment of Crohn’s disease over a three-year period: a Canadian assessment
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 18-22, 2013, New Orleans

Lachaine J, Feagan BG, Martel MJ, Beauchemin C, McHugh K
The impact of TNF inhibitors for Crohn’s disease on health care resource utilization: an analysis using the RAMQ database
Canadian Digestive Disease Week (CDDW), Mar 1-4, 2013, Victoria

Lachaine J, Beauchemin C, Lapierre ME, Masson E, Drapeau JB, Groulx J
Cost-effectiveness of an intensive intervention program in the control of allergic rhinitis due to ragweed pollen in Quebec, Canada
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 3-7, 2012, Berlin

Lachaine J, Moreau A, Beauchemin C, Mathurin K
Economic impact of scoliosis in Canada: a RAMQ database analysis
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 3-7, 2012, Berlin

Lachaine J, Lacroix A, Beauchemin C, Hurry M
Cost and health care resources utilization in the management of Cushing's disease: an analysis based on the RAMQ database
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 3-7, 2012, Berlin

Lachaine J, Serri O, Beauchemin C, Hurry M
Health care resources utilization and costs associated with the management of patients with acromegaly: an analysis based on the RAMQ database
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 3-7, 2012, Berlin

Beauchemin C, Johnston JB, Lapierre M, Aissa F, Lachaine J
Relation between progression-free survival and overall survival in chronic lymphocytic leukemia
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 3-7, 2012, Berlin

Lachaine J, Beauchemin C, Crochard A, Bineau S
The impact of memantine and cholinesterase inhibitors initiation for Alzheimer's disease on the use of antipsychotics agents: analysis using the RAMQ database
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 3-7, 2012, Berlin

Lachaine J, Hurry MV, Beauchemin C, Koch C, Lacroix A
Characteristics of patients with Cushing’s disease and their therapies: an analysis based on the RAMQ database for the population of Quebec province
Canadian Society of Endocrinology and Metabolism (CSEM), Oct 10-13, 2012, Vancouver

Beauchemin C, Johnston JB, Lapierre M, Aissa F, Lachaine J
Relationship between progression-free survival and overall survival in chronic lymphocytic leukemia
European Society for Medical Oncology (ESMO), Sep 28-Oct 2, 2012, Vienna

Beauchemin C, Cooper D, Lapierre M, Yelle L, Lachaine J
Progression-free survival as a surrogate for overall survival in metastatic breast cancer
European Society for Medical Oncology (ESMO), Sep 28-Oct 2, 2012, Vienna

Lachaine J, Yen L, Beauchemin C, Hodgkins P
Factors associated with treatment adherence and persistence in Canadian patients with ulcerative colitis (UC): analysis of prescription claims from the RAMQ database
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Asia-Pacific Congress, Sep 2-4, 2012, Taipai

Abdalla N, Barbeau M, Lachaine J
Budget impact analysis: do Canadian guidelines meet the needs of public drug plan managers?
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 2-6, 2012, Washington, DC

Lachaine J, Feagan BG, Martel MJ, Beauchemin C, McHugh K
The impact of TNF inhibitors for Crohn’s disease on health care resource utilization: an analysis using the RAMQ database
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 2-6, 2012, Washington, DC

Lachaine J, Beauchemin C, Flavin J
Risk of complications in type II diabetic patients with renal impairment: an analysis of the RAMQ database
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 2-6, 2012, Washington, DC

Lachaine J, Beauchemin C, Flavin J
Health care resources utilization and cost for hypoglycemia and metabolic acidosis in type II diabetes: an analysis of the RAMQ database
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 2-6, 2012, Washington, DC

Lachaine J, Beauchemin C, Mathurin K, Blouin J
Productivity losses associated with vision impairment in Canada
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 2-6, 2012, Washington, DC

Lachaine J, Beauchemin C, Mathurin K, Gilbert D, Beillat M, Corson H
Cost-effectiveness of asenapine in the treatment of bipolar I disorder in Canada
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 2-6, 2012, Washington, DC

Lachaine J, Beauchemin C, Mathurin K, Gilbert D, Beillat M, Corson H
Cost-effectiveness of asenapine in the treatment of schizophrenia in Canada
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 2-6, 2012, Washington, DC

Lachaine J
Advanced pharmacoeconomics: the QALY - pros and cons
Canadian Association for Population Therapeutics (CAPT), May 6-8, 2012, Montreal

Lachaine J, Beauchemin C, Barbeau M
Cost-effectiveness of asenapine in the treatment of schizophrenia and bipolar disorder in Canada
College International de Neuropharmacologie (CINP), Jun 3-7, 2012, Stockholm

Lachaine J, Beauchemin C, Barbeau M
Tobramycin inhaled solution utilization by cystic fibrosis patients: an analysis with the RAMQ database
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 5-8, 2011, Madrid

Lachaine J, Beauchemin C, Yen L, Hodgkins P
Economic impact of medication adherence and persistence in the treatment of ulcerative colitis in canada: analyses with the RAMQ database
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 5-8, 2011, Madrid

Lachaine J, Beauchemin C, Martel MJ, Parison D
Coexistence of immuno-mediated inflammatory diseases: an analysis of the Quebec administrative health databases
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 5-8, 2011, Madrid

Lachaine J, Beauchemin C, Crochard A, Bineau S
Impact of initiation of treatment with memantine or cholinesterase inhibitors (ChEI) on the use of psychotropic drugs: analysis of RAMQ database
Clinical Trial in Alzheimer’s Disease (CTAD), Nov 3-5, 2011, San Diego

Touchon J, Lachaine J, Beauchemin C, Crochard A, Rive B, Bineau S
Memantine delays the admission of Alzheimer’s disease patients to nursing home: cost-effectiveness analysis in France
Clinical Trial in Alzheimer’s Disease (CTAD), Nov 3-5, 2011, San Diego

Lachaine J, Yen L, Beauchemin C, Hodgkins P
Determinants of adherence and persistence in the treatment of ulcerative colitis in Canada: analyses with the RAMQ database
United European Gastroenterology Week (UEGW), Oct 22-26, 2011, Stockholm

Lachaine J, Beauchemin C
Impact of ChEI treatment initiation on psychotropics use. Analyses with the RAMQ database
European Federation of Neurological Societies (EFNS), Sep 10-13, 2011, Budapest

Lachaine J, Beauchemin C, Amer R
Economic evaluation of dexmedetomidine for sedation in the intensive care
Canadian Society for Hospital Pharmacists (CSHP), Aug 6-10, 2011, Vancouver

Lachaine J, Beauchemin C, Martel MJ, Goyette A
Analysis of health care resources utilization in the management of juvenile idiopathic arthritis
European Congress of Rheumatology (EULAR), May 25-26, 2011, London

Lachaine J, Beauchemin C
Economic evaluation of dexmedetomidine for sedation in the intensive care unit
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 21-25, 2011, Baltimore

Lachaine J, Beauchemin C, Martel MJ, Goyette A
Dose variations with adalimumab and infliximab in the treatment of Crohn’s disease: a Canadian assessment
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 21-25, 2011, Baltimore

Lachaine J, Beauchemin C, Martel MJ, Goyette A
Health care resources utilization in the management of juvenile idiopathic arthritis: analyses with the RAMQ database
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 21-25, 2011, Baltimore

Lachaine J, Beauchemin C, Martel MJ, Goyette A
Dose variations with adalimumab and infliximab in the treatment of Crohn’s disease: a Canadian assessment
Canadian Digestive Disease Week (CDDW), Feb 26-Mar 1, 2011, Vancouver

Lachaine J, Beauchemin C, Yen L, Hodgkins P
Medication adherence and persistence in the treatment of ulcerative colitis. Analysis with RAMQ data
Canadian Digestive Disease Week (CDDW), Feb 26-Mar 1, 2011, Vancouver

Lachaine J, Beauchemin C, Martel MJ, Goyette A
Dose variations with adalimumab and infliximab in the treatment of Crohn’s disease: a Canadian assessment
European Crohn's and Colitis Organization (ECCO), Feb 24-26, 2011, Dublin

Touchon J, Lachaine J, Beauchemin C, Crochard A, Bineau S
Memantine delays the admission of Alzheimer’s disease patients to nursing home: cost-effectiveness analysis in France
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 6-9, 2010, Prague

Lachaine J, Beauchemin C, Legault M, Bineau S
Impact of memantine treatment initiation on psychotropics use: analyses with the RAMQ database
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 6-9, 2010, Prague

Lachaine J, Beauchemin C, Yen L, Hodgkins P
Medication adherence and persistence in the treatment of ulcerative colitis: analysis with RAMQ database
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 6-9, 2010, Prague

Martel MJ, Ackad N, Lachaine J
Incidence and prevalence of endometriosis: administrative health databases study from Quebec
International Society for Pharmacoepidemiology (ISPE), Aug 19-22, 2010, Brighton

Lachaine J, Beauchemin C, Legault M
Economic evaluation of escitalopram to treat major depressive disorder
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 15-19, 2010, Atlanta

Lachaine J, Beauchemin C, Legault M, Le Lay A
Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer’s disease
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 15-19, 2010, Atlanta

Lachaine J, Beauchemin C, Hodgkins P, Sasane R
Treatment patterns in attention-deficit/hyperactivity disorder: analyses with the RAMQ database
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 15-19, 2010, Atlanta

Lachaine J, Beauchemin C, Sasane R, Hodgkins P
Adherence and persistence to treatment in patients with attention-deficit/hyperactivity disorder: analyses with RAMQ database
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 15-19, 2010, Atlanta

Lachaine J, Beauchemin C, Ramos E
Use of spironolactone to treat congestive heart failure post-myocardial infarction. Analyses with the RAMQ database
Canadian Cardiovascular Congress (CCC), Oct 24-28, 2009, Edmonton

Lachaine J, Beauchemin C, Ramos E
Use of spironolactone in the treatment of congestive heart failure
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe Congress, Oct 24-27, 2009, Paris

Lachaine J, Beauchemin C
Cost-utility analysis of topical diclofenac for the treatment of osteoarthritis of the knee
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe Congress, Oct 24-27, 2009, Paris

Lachaine J, Beauchemin C, Ramos E
Use of spironolactone to treat congestive heart failure post-myocardial infarction. Analyses with the RAMQ database
International Society for Pharmacoepidemiology (ISPE), Aug 16-19, 2009, Providence

Lachaine J, Beauchemin C
Analyse coût-utilité du traitement de l’ostéoarthrite du genou par le diclofénac topique
Réseau québécois de recherche sur l’usage des médicaments (RQRUM), Jun 2-3, 2009, Montreal

Lachaine J, Beauchemin C, Ramos E
Utilisation de la spironolactone dans le traitement de l’insuffisance cardiaque
Réseau québécois de recherche sur l’usage des médicaments (RQRUM), Jun 2-3, 2009, Montreal

Lachaine J, Beauchemin C, Landry PA
Caractéristiques cliniques et économiques des patients atteints de fibromyalgie
Réseau québécois de recherche sur l’usage des médicaments (RQRUM), Jun 2-3, 2009, Montreal

Lachaine J, Beauchemin C, Landry PA
Clinical and economic characteristics of patients with fibromyalgia
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 16-20, 2009, Orlando

Lachaine J
Cost-utility analysis of topical diclofenac for the treatment of osteoarthritis of the knee
Canadian Agency for Drugs and Technologies in Health (CADTH), Apr 5-7, 2009, Ottawa

Lachaine J, Martel MJ, Poulin YP, Langley R
Health care resource utilization by patients with psoriasis
American Academy of Dermatology (AAD), Mar 6-10, 2009, San Francisco

Lachaine J, Martel MJ, Poulin YP, Langley R
Health care resources utilisation by patients with psoriasis
International Society for Pharmacoepidemiology (ISPE), Aug 16-21, 2008, Copenhagen

Lachaine J, Martel MJ, Poulin YP, Langley R
Health care resources utilisation by patients with psoriasis
Canadian Association for Population Therapeutics (CAPT), Jul 27-Aug 1, 2008, Quebec

Lachaine J, Lescrauwaet B, Sauriol L
Treatment patterns in type-2 diabetes management
Canadian Diabetes Association (CDA), Oct 18-21, 2006, Toronto

Lachaine J, Lescrauwaet B, Sauriol L
Health care resources consumption in type-2 diabetes management
Canadian Diabetes Association (CDA), Oct 18-21, 2006, Toronto

Lachaine J, Lescrauwaet B, Sauriol L
Treatment patterns in type-2 diabetes management
Canadian Association for Population Therapeutics (CAPT), May 10-13, 2006, Toronto

Lachaine J, Lescrauwaet B, Sauriol L
Health care resources consumption in type-2 diabetes management
Canadian Association for Population Therapeutics (CAPT), May 10-13, 2006, Toronto

Lachaine J, Tarride JE
Painful neuropathic disorders, an analysis of the RAMQ database
Canadian Pain Society (CPS), May 11-14, 2005, Halifax

Lachaine J, Tarride JE
Resource utilization in diabetic painful neuropathy patients. An analysis of the RAMQ database
Canadian Pain Society (CPS), May 11-14, 2005, Halifax

Lachaine J, Tarride JE
Painful neuropathic disorders: an analysis of the Régie de l’assurance maladie du Québec (RAMQ) database
Canadian Association for Population Therapeutics (CAPT), Apr 17-19, 2005, Vancouver

Lachaine J, Zlateva G, Charbonneau C
Treatment patterns and health care resources utilisation by patients with asthma and COPD
Canadian Association for Population Therapeutics (CAPT), Apr 17-19, 2005, Vancouver

Lachaine J, Merickle E, Montpetit M
A model of assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian Working Group Guidelines
Canadian Association for Population Therapeutics (CAPT), Apr 17-19, 2005, Vancouver

Lachaine J, Tarride JE
Resource utilization in diabetic painful neuropathy patients
Canadian Association for Population Therapeutics (CAPT), Jun, 2004, Winnipeg

Lachaine J, Ali F, Merikle E
Persistence and adherence to antihypertensive agents
Canadian Association for Population Therapeutics (CAPT), Jun, 2004, Winnipeg

Lachaine J, Yelle L, Kaiser L, Dufour A, Hopkins S, Deuson R
Quality of life and economic impacts of chemotherapy induced nausea and vomiting in the context of current practice in Canada
MASCC/ISOO, Jun, 2004, Miami

Lachaine J, Ali F, Merikle E
Persistence and adherence to antihypertensive agents
American Society of Hypertension (ASH), Jun, 2004, New-York

Lachaine J, Tarride JE
Persistence and adherence to cholesterol lowering agents: evidences from RAMQ data
Canadian Association for Population Therapeutics (CAPT), Mar 30-Apr 1, 2003, Quebec

Lachaine J, Yelle L, Kaizer L, Dufour A, Desjardins B, Desjardins B, Deuson R
Burden of chemotherapy-induced nausea and vomiting in the context of current Canadian practice
European Organization for Research and Treatment of Cancer (EORTC), 2003, Bruxelles

Lachaine J, Yelle L, Kfaizer L, Dufour A, Desjardins B, Desjardins B, Deuson R
Incidence and burden of chemotherapy-induced nausea and vomiting in the context of current practice in Ontario and Quebec (Canada)
American Society of Clinical Oncology (ASCO), 2003

Lachaine J, Bradley-Kennedy C
Health care resources utilization in chronic obstructive pulmonary disease
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May, 2002, Arlington